FDA Grants Fast Track Designation to Telix's BiPASS Prostate Imaging Program
TLX sits 76% above its 52-week low of $6.28.
Summary
Telix's BiPASS pre-biopsy prostate imaging program received FDA Fast Track designation, potentially accelerating its path to an NDA submission and expanding access to PSMA-PET imaging for a larger patient population.
Key Events · Product Development and Regulatory · TLX
-
FDA Fast Track Designation Granted
On September 30, 2026, the FDA granted Fast Track designation to Telix's BiPASS program, recognizing its potential to address an unmet need in pre-biopsy prostate cancer diagnosis.
-
Expedited NDA Pathway
Fast Track enables more frequent FDA engagement and may allow expedited review of the planned NDA for Illuccix and Gozellix in the pre-biopsy setting.
-
Large Addressable Market
Over 3 million prostate biopsies are performed globally each year, with up to 75% producing negative results — the imaging-first approach could reduce unnecessary biopsies by nearly 50% based on prior PRIMARY studies.
-
Phase 3 Enrollment Completed
Telix completed enrollment in the Phase 3 BiPASS study of Illuccix and Gozellix on September 2, 2026, and has positively engaged with the FDA on the NDA pathway.
Analysis · TLX · Life Sciences
A meaningful regulatory milestone has been reached: the FDA granted Fast Track designation to Telix's BiPASS program, which evaluates 68Ga-PSMA-PET imaging alongside MRI for pre-biopsy prostate cancer detection. This designation enables more frequent FDA engagement and potentially expedited review of the planned NDA. It follows the September 2 completion of Phase 3 enrollment and builds on the company's recent US$1.65B merger with ITM, reinforcing the strategic value of its precision diagnostics franchise.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $11.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $6.28 to $13.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.